Merus partners with Partner Therapeutics for U.S. rights to Zeno in NRG1+ cancer. Updated petosemtamab data emerge as a key ...
Replimune's BLA submission and promising pipeline drugs are set to impact the global melanoma therapeutics market. Read more ...
The FDA granted approval to nilotinib (Danziten) on November 14, 2024, for the treatment of adult patients with newly ...
Biocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting ...
Monday announced an agreement with Partner Therapeutics, Inc. to commercialize Zenocutuzumab for the treatment of ...
Zacks.com on MSN6d
FDA Accepts GSK's BLA for Blenrep Combos in Multiple MyelomaGSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a ...
Omeros ( OMER, Financials) announced progress toward resubmitting its biologics license application for narsoplimab, its ...
MyChesCo on MSN5d
Johnson & Johnson Advances Ulcerative Colitis Treatment with FDA Filing for TREMFYA® Subcutaneous RegimenSPRING HOUSE, PA – Johnson & Johnson (NYSE: JNJ) has submitted a supplemental Biologics License Application (sBLA) to the U.S ...
Nov. 22, 2024 /PRNewswire/ -- StemCyte Inc., a wholly owned subsidiary of StemCyte International Ltd., announced today that ...
On November 21, 2024, Replimune Group, Inc. (NASDAQ: REPL) made significant strides in the advancement of its lead product candidate, RP1. The company announced the submission of a biologics license ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback